Stocks: Allergan plc (AGN) Shares Sold by Armstrong Shaw Associates Inc. CT

Stocks: Allergan plc (AGN) Shares Sold by Armstrong Shaw Associates Inc. CT

Armstrong Shaw Associates Inc. CT decreased its stake in Allergan plc (NYSE:AGN) by 5.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,432 shares of the company’s stock after selling 2,716 shares during the period. Allergan plc accounts for 2.7% of Armstrong Shaw Associates Inc. CT’s holdings, making the stock its 22nd largest position. Armstrong Shaw Associates Inc. CT’s holdings in Allergan plc were worth $10,616,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the company. Baupost Group LLC MA increased its stake in shares of Allergan plc by 71.5% in the fourth quarter. Baupost Group LLC MA now owns 3,432,603 shares of the company’s stock valued at $720,881,000 after buying an additional 1,430,625 shares during the period. Swedbank increased its stake in shares of Allergan plc by 0.6% in the third quarter. Swedbank now owns 645,371 shares of the company’s stock valued at $148,635,000 after buying an additional 3,940 shares during the period. First Personal Financial Services increased its stake in shares of Allergan plc by 22.7% in the third quarter. First Personal Financial Services now owns 17,175 shares of the company’s stock valued at $3,956,000 after buying an additional 3,174 shares during the period. Peregrine Capital Management LLC bought a new stake in shares of Allergan plc during the third quarter valued at approximately $16,404,000. Finally, State Treasurer State of Michigan increased its stake in shares of Allergan plc by 0.5% in the third quarter. State Treasurer State of Michigan now owns 138,152 shares of the company’s stock valued at $31,818,000 after buying an additional 700 shares during the period. Hedge funds and other institutional investors own 86.40% of the company’s stock.

Shares of Allergan plc (NYSE:AGN) opened at 231.08 on Friday. Allergan plc has a 12 month low of $184.50 and a 12 month high of $261.27. The company has a market cap of $77.43 billion, a PE ratio of 7.20 and a beta of 1.07. The stock has a 50 day moving average of $239.15 and a 200-day moving average of $222.31.

Allergan plc (NYSE:AGN) last issued its earnings results on Tuesday, May 9th. The company reported $3.35 EPS for the quarter, topping the consensus estimate of $3.32 by $0.03. Allergan plc had a return on equity of 7.21% and a net margin of 100.04%. The business had revenue of $3.57 billion during the quarter, compared to the consensus estimate of $3.53 billion. During the same quarter last year, the company earned $3.04 EPS. The firm’s revenue was up 5.1% compared to the same quarter last year. Equities analysts forecast that Allergan plc will post $16.09 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 15th. Shareholders of record on Thursday, May 18th will be paid a $0.70 dividend. The ex-dividend date of this dividend is Tuesday, May 16th. This represents a $2.80 annualized dividend and a yield of 1.21%.

Several analysts have commented on AGN shares. Goldman Sachs Group Inc restated a “buy” rating and set a $250.00 target price (up from $240.00) on shares of Allergan plc in a report on Wednesday, January 18th. Vetr upgraded shares of Allergan plc from a “hold” rating to a “buy” rating and set a $224.07 price objective on the stock in a report on Monday, January 23rd. Piper Jaffray Companies set a $205.00 price objective on shares of Allergan plc and gave the company a “hold” rating in a report on Wednesday, February 22nd. Leerink Swann lifted their price objective on shares of Allergan plc to $280.00 and gave the company a “buy” rating in a report on Thursday, February 9th. Finally, Credit Suisse Group AG reiterated a “buy” rating and issued a $274.00 price objective on shares of Allergan plc in a report on Tuesday, February 14th. Six investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $267.21.

In other Allergan plc news, Director Paul Bisaro sold 70,000 shares of the firm’s stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $246.68, for a total value of $17,267,600.00. Following the completion of the transaction, the director now owns 274,226 shares in the company, valued at approximately $67,646,069.68. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.27% of the stock is owned by company insiders.

About Allergan plc

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Related posts

Leave a Comment